{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:20:22Z","timestamp":1790461222795,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Galapagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Filgotinib is an oral, once\u2010daily, Janus kinase 1 preferential inhibitor approved for treatment of ulcerative colitis (UC) following the phase 2b\/3 SELECTION trial. Identification of patient populations and factors associated with long\u2010term treatment response trajectories may improve UC management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to identify and describe distinct patient subgroups of response to filgotinib based on partial Mayo Clinic Score (pMCS) trajectories over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In these <jats:italic>post hoc<\/jats:italic> analyses of SELECTION, group\u2010based trajectory modeling (GBTM) was applied to pMCS to describe groups of distinct, symptom\u2010based patient trajectories using data from patients who responded to filgotinib 200 or 100\u00a0mg and continued receiving filgotinib up to week 58. Patient demographics, disease characteristics, and week 10 response were compared between the groups. Achievement of a patient\u2010level multi\u2010component endpoint of comprehensive disease control (CDC) was assessed in each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GBTM identified five distinct patient populations with different response trajectories; 67.5% of patients had beneficial trajectories. The beneficial trajectory groups generally had higher proportions of patients who were recently diagnosed (&lt;1\u00a0year), were receiving filgotinib 200\u00a0mg and were biologic\u2010naive versus the relapsing trajectory groups (4%\u20139% vs. 4%\u20135%; 43%\u201365% vs. 36%\u201346%; 54%\u201370% vs. 35%\u201358%, respectively). Furthermore, 55.4% of patients had sustained beneficial trajectories, with low baseline endoscopic subscores (\u226543% of patients had a subscore of 2) and strong week 10 FCP responses (\u226561% of patients with &gt;50% decrease in FCP from baseline). Sustained beneficial trajectory groups had a higher probability of achieving CDC at week 58 than other groups (31%\u201332% vs. 0%\u20137%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Beneficial long\u2010term response trajectories and achievement of CDC with filgotinib were associated with being biologic\u2010naive and having less severe disease at baseline. Early estimation of sustained and CDC may facilitate patient identification and development of personalized management strategies in UC.<\/jats:p><\/jats:sec><jats:sec><jats:title>ClinicalTrials.gov Identifier<\/jats:title><jats:p>NCT02914522.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ueg2.12686","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:59:46Z","timestamp":1729864786000},"page":"1243-1255","source":"Crossref","is-referenced-by-count":9,"title":["Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-9822","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[{"name":"Department of Medicine I University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[{"name":"Alimentiv, Inc.  London Ontario Canada"},{"name":"Division of Gastroenterology Department of Medicine Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-7075","authenticated-orcid":false,"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Li\u00e8ge  Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":false,"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Dron","sequence":"additional","affiliation":[{"name":"Cytel  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9363-6077","authenticated-orcid":false,"given":"Corinne","family":"Jamoul","sequence":"additional","affiliation":[{"name":"Galapagos NV  Mechelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-5163","authenticated-orcid":false,"given":"Haridarshan","family":"Patel","sequence":"additional","affiliation":[{"name":"Galapagos NV  Mechelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Harris","sequence":"additional","affiliation":[{"name":"Galapagos S.r.l  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Taliadouros","sequence":"additional","affiliation":[{"name":"Galapagos B.V  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-1004","authenticated-orcid":false,"given":"Alessandra","family":"Oortwijn","sequence":"additional","affiliation":[{"name":"Galapagos B.V  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin\u2010Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Nancy University Hospital  Nancy France"},{"name":"INSERM NGERE University of Lorraine  Nancy France"},{"name":"INFINY Institute Nancy University Hospital  Nancy France"},{"name":"FHU\u2010CURE Nancy University Hospital  Nancy France"},{"name":"Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9 \u2010 Hartmann Paris IBD Center  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021\u20100080"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjaa232"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802600961"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(16)32126\u20102"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010med\u2010052919\u2010120048"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496739"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa050516"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00666\u20108"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215734"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606910"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1900750"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad018"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac200"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000705476.74327.9a"},{"key":"e_1_2_10_16_1","volume-title":"Summary of product characteristics, Jyseleca","author":"Galapagos NV","year":"2023"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/clep.s265287"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.clinpsy.121208.131413"},{"key":"e_1_2_10_19_1","first-page":"483","article-title":"Group\u2010based trajectory modeling to identify response patterns to ozanimod treatment in patients with ulcerative colitis","volume":"11","author":"Schreiber S","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad212.0118"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000953244.57163.2b"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad212.0675"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad212.0864"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxab002"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000360229"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab232.674"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001987"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad033"},{"key":"e_1_2_10_29_1","article-title":"Using group\u2010based trajectory modeling to identify response patterns to ozanimod treatment in patients with ulcerative colitis [abstract]","author":"Schreiber S","year":"2023","journal-title":"UEGW"},{"key":"e_1_2_10_30_1","article-title":"Mirikizumab achieved comprehensive disease control in patients with ulcerative colitis from phase 3 LUCENT\u20101 and LUCENT\u20102 trials [abstract]","author":"Navabi S","year":"2023","journal-title":"ACG"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000777044.92295.4d"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215598806"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.12686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:56:48Z","timestamp":1732165008000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.12686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/ueg2.12686"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.12686","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}